We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 154% below its sector, cheaper than its peers on earnings.
PT Kimia Farma (Persero) Tbk, an Indonesian entity, is engaged in the manufacturing and sale of a diverse range of products, including pharmaceuticals, herbal remedies, iodine, salts, quinine and its derivatives, and vegetable oils. Its business operations are structured across several key divisions: Manufacturing, Distribution, Retail, and Other Services. Beyond these, the company's portfolio extends to the production and sale of generic, ethical, licensed, and narcotic pharmaceuticals, along with over-the-counter drugs, medical equipment, raw materials, and cosmetics. Its extensive distribution network ensures products reach various outlets, including pharmacies, hospital pharmacies, medical centers, and drugstores. Established in 1817, the company maintains its headquarters in Jakarta, Indonesia.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save KAEF.JK and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
